Efinopegdutide Real Results: Weight Loss Timeline & What Patients Report

Introduction

Efinopegdutide’s main published efficacy data comes from the Romero-Gomez 2023 Journal of Hepatology phase 2a trial: 145 adults with MASH-related liver fat (MRI-PDFF at least 10%) randomized to efinopegdutide 10 mg or semaglutide 1.0 mg weekly for 24 weeks. Results showed 8.5% weight loss for efinopegdutide vs 7.1% for semaglutide and 72.7% vs 42.3% liver fat reduction.

This article walks through the trial timeline, what to expect month by month, and how efinopegdutide compares to other GLP-1-class options.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

When Does Efinopegdutide Weight Loss Start?

Phase 2 patients showed appetite suppression within the first week and visible weight loss by week 2 to 4. Mean weight loss at 4 weeks was about 2 to 3% of baseline. By week 12, mean loss was around 5 to 6%, and by 24 weeks, 8.5% at the 10 mg dose.

Quick Answer: Phase 2a MASH trial 24 weeks: 8.5% mean weight loss at 10 mg

The trajectory is similar to other GLP-1-class drugs in the early weeks. Differences emerge in the 12 to 24 week range as efinopegdutide’s curve continues falling at a slightly faster slope than semaglutide’s.

What Does the 24-week Curve Look Like?

The Romero-Gomez 2023 trial showed weight loss building progressively through 24 weeks with no plateau. Efinopegdutide and semaglutide curves were similar through week 12, then diverged with efinopegdutide pulling ahead through week 24.

Longer trials would likely show continued weight loss for both drugs. Phase 3 trials at 52 to 72 weeks would provide the comparison data the field needs.

How Much Fat vs Lean Mass Is Lost?

Detailed body composition (DEXA) data for efinopegdutide isn’t published as prominently as for pemvidutide. Phase 2 reports suggest the fat-to-lean loss ratio is similar to semaglutide’s, which is somewhat less favorable than pemvidutide’s reported pattern.

Phase 3 trials should include more detailed body composition analyses if Merck wants to differentiate efinopegdutide on this dimension.

How Does Efinopegdutide Affect Liver Fat?

This is where efinopegdutide stands out. MRI-PDFF reductions of 72.7% at 24 weeks at 10 mg in MASH patients are larger than:

Semaglutide 1.0 mg in the same trial: 42.3%.

Pemvidutide 1.2 mg in IMPACT MASH at 24 weeks: 57.1%.

Resmetirom 100 mg in MAESTRO-NASH at 52 weeks: about 30 to 40%.

The strong liver-fat effect is the primary basis for efinopegdutide’s positioning as a MASH drug.

What Did the MASH Resolution Data Show?

The Romero-Gomez 2023 trial didn’t require liver biopsy at endpoint, so MASH resolution rates aren’t directly reported. The published efficacy is based on liver fat (MRI-PDFF), ALT, and weight endpoints.

Phase 2b efinopegdutide trials with biopsy endpoints are ongoing. MASH resolution rates will be a primary endpoint for phase 3.

What Is the Typical Month-by-month Pattern?

Month 1: Titration to 10 mg over about 4 weeks. Mild to moderate GI symptoms peak in early weeks. Weight loss 2 to 3%. Appetite suppression strong.

Month 2: Maintenance dose. Side effects ease for most patients. Weight loss 4 to 5% cumulative.

Month 3: Continued steady weight loss. Cumulative 5 to 6%. Liver fat clearly improving on imaging.

Month 4 to 6 (weeks 13 to 24): Weight loss continues. Cumulative 7 to 9% at endpoint. Liver fat down 60 to 75%.

Beyond 24 weeks isn’t yet documented from published phase 2 efinopegdutide data.

Do All Patients Respond the Same Way?

No. Individual variation is significant. In the phase 2a MASH trial, response heterogeneity was similar to other GLP-1 trials: some patients had strong weight loss (over 15%), others had more modest results (under 5%).

Adherence to weekly dosing, dietary changes, and activity all affect individual response. Patients can usually tell within 8 to 12 weeks whether they’re on the upper or lower end of the response distribution.

How Does Efinopegdutide Compare to Semaglutide for Weight Loss?

In the direct head-to-head trial: 8.5% vs 7.1% at 24 weeks. Modestly better for efinopegdutide.

The semaglutide dose in that trial was 1.0 mg, which is the standard diabetes dose, not the 2.4 mg obesity dose. Direct comparison to Wegovy® 2.4 mg from STEP 1 (14.9% at 68 weeks) isn’t possible without different trial conditions.

Wegovy-level dosing might allow semaglutide to match or exceed efinopegdutide’s weight loss while still falling short on liver fat reduction.

How Does Efinopegdutide Compare to Tirzepatide?

No direct head-to-head exists. Tirzepatide’s SURMOUNT-1 produced 20.9% weight loss at 72 weeks at 15 mg. Efinopegdutide’s 8.5% at 24 weeks at 10 mg can’t be directly compared due to different doses and durations.

Tirzepatide likely has greater weight loss potential. Efinopegdutide has stronger liver fat effects.

How Does Efinopegdutide Compare to Pemvidutide?

Both are dual GLP-1/glucagon agonists with phase 2 data in MASH and obesity. Pemvidutide phase 2 showed 15.6% weight loss at 48 weeks at 2.4 mg; efinopegdutide showed 8.5% at 24 weeks at 10 mg. The trials are different in duration and population, making direct comparison difficult.

Efinopegdutide may have larger liver fat effects (72.7% vs 57.1% at 24 weeks). Pemvidutide may have better lean mass preservation. A direct head-to-head would settle the question but is unlikely given the regulatory and competitive landscape.

What About HbA1c and Metabolic Markers?

Efinopegdutide produced modest HbA1c reductions in phase 2 (0.3 to 0.5 percentage points), more than pemvidutide’s flat profile but less than pure GLP-1 drugs.

Liver enzymes (ALT, AST) improved substantially in the MASH trial, consistent with the strong liver fat reductions. This is meaningful for MASH patients with elevated baseline liver enzymes.

What Can Patients Expect After Stopping?

Weight regain after stopping is expected. The STEP 1 extension showed about two-thirds of semaglutide weight loss returns within one year. Efinopegdutide is likely similar.

Liver fat may also reaccumulate. The 24-week phase 2 data showed strong reductions during treatment but didn’t follow patients after discontinuation. Phase 3 trials with longer follow-up should address this.

What Does TrimRx Offer in the Meantime?

Efinopegdutide isn’t on the TrimRx formulary because it isn’t FDA-approved. The free assessment quiz routes patients to compounded semaglutide or tirzepatide based on goals and clinical fit.

When efinopegdutide is approved, TrimRx will evaluate carrying it. Patients with significant MASH and obesity may particularly benefit.

Key Takeaway: ALT reduction: about 30 to 40%

What’s the Typical Body Composition Change?

Body composition during efinopegdutide treatment shifts toward less fat mass and more relative lean mass percentage. Detailed DEXA data isn’t as prominently published as for pemvidutide, but phase 2 reports suggest fat-to-lean loss ratios similar to semaglutide rather than the more favorable pattern reported for pemvidutide.

For patients prioritizing lean mass preservation (athletes, older adults, people with sarcopenia risk), resistance training plus adequate protein intake (1.2 to 1.6 g/kg/day) is the standard recommendation regardless of which GLP-1 drug is used.

How Do Liver Enzymes Change Over Time?

In the phase 2a MASH trial, ALT dropped by 30 to 40% over 24 weeks at the 10 mg dose. AST followed a similar trend. These are clinically meaningful reductions in patients with elevated baseline enzymes.

For patients with MASH and elevated transaminases, the liver enzyme drop is one of the more visible indicators of treatment response. Normalization of ALT and AST often occurs within 12 to 24 weeks of starting efinopegdutide.

Patients with normal baseline enzymes don’t see meaningful drops because the enzymes are already near the floor.

What About Blood Pressure Changes?

Phase 2 trials showed modest blood pressure reductions, typically 3 to 5 mmHg systolic at the 10 mg dose. The effect is partly weight-loss driven and partly GLP-1-specific vascular effects.

Patients on antihypertensive medications may need dose reductions over time. Orthostatic symptoms (dizziness when standing up) can occur, especially during periods of reduced food and fluid intake.

What About Lipid Changes?

Triglycerides typically drop by 20 to 30% with significant GLP-1-driven weight loss. HDL is often neutral to slightly improved. LDL changes are smaller for efinopegdutide than for pemvidutide based on available data.

Lipid panel monitoring 3 to 4 months after starting therapy is reasonable to confirm trends.

What’s the Response Pattern Over the First 6 Months?

Month 1: Titration. Weight loss 2 to 3%. Side effects most prominent.

Month 2: Maintenance dose reached. Weight loss 4 to 5%. Side effects easing. Liver fat starting to drop.

Month 3: Steady weight loss. Cumulative 5 to 6%. Liver fat clearly improved on imaging.

Month 4: Continued loss. Cumulative 7 to 8%. ALT reductions clear.

Month 5: Continued loss. Cumulative 8 to 9%.

Month 6 (24 weeks): Mean 8.5% loss. Liver fat down 60 to 75%.

How Does Weight Loss Correlate with Liver Fat Reduction?

Weight loss and liver fat reduction are correlated but not perfectly proportional. Efinopegdutide produces more liver fat reduction per kg of weight loss than semaglutide does, reflecting the direct glucagon-driven hepatic effects.

That means patients with significant baseline liver fat see proportionally more liver benefit from efinopegdutide than they would from a pure GLP-1 drug at equivalent weight loss.

What Does the Personalized Treatment Plan From TrimRx Consider?

The TrimRx free assessment quiz screens for liver health (including known MASH or fatty liver diagnoses), weight loss goals, medical comorbidities, and other factors that affect which GLP-1 drug is the best fit.

Currently the quiz routes patients to compounded semaglutide or tirzepatide. When efinopegdutide is approved and added, patients with significant MASH would be candidates for efinopegdutide specifically.

How Do Results Compare Across Patient Subgroups?

Phase 2 trial data didn’t show dramatic differences by sex, race, or age subgroups, but sample sizes were too small for strong subgroup analysis. Phase 3 trials will provide more granular data.

Patients with significant baseline liver fat see more dramatic improvements in liver-related markers compared to patients with normal liver fat. Weight loss is similar across these groups.

What Happens During Weight Loss Plateaus?

Most patients see weight loss slow after 4 to 6 months. True plateaus (no weight change for 4+ weeks at maintenance dose) may occur as the body adapts metabolically.

Options at plateau: continue current treatment (some patients break through with patience), increase activity, refine diet, or consider switching to a different GLP-1 drug.

How Does Response Correlate with Adherence?

Trial adherence in phase 2 efinopegdutide studies was high (around 90% completion). Real-world adherence is typically lower.

A practical rule: at least 80% of weekly doses on schedule for 12 months should be the goal for optimal results.

What Does the Personalized Treatment Plan From TrimRx Consider?

The TrimRx free assessment quiz screens for liver health, weight loss goals, medical comorbidities, and other factors. Currently the quiz routes patients to compounded semaglutide or tirzepatide.

When efinopegdutide is approved and added, patients with significant MASH would be candidates specifically.

Bottom line: Direct comparison to tirzepatide or pemvidutide doesn’t exist yet

FAQ

How Fast Do Efinopegdutide Results Show Up?

Weight loss usually begins within the first 1 to 2 weeks. By week 4, most patients have lost 2 to 3% of baseline weight.

What’s the Maximum Weight Loss Seen with Efinopegdutide?

Phase 2 mean at 24 weeks was 8.5%. Individual patients with strong responses lost more (over 15% in some cases).

Does Efinopegdutide Work Without Diet Changes?

The drug suppresses appetite, naturally reducing intake. Adding dietary changes and activity produces more loss.

Will I Plateau on Efinopegdutide?

The 24-week phase 2 data showed continued weight loss with no plateau. Longer trials are needed to know.

How Do Phase 2 Results Translate to Real-world Expectations?

Trial patients have more support and structure. Real-world averages are typically 70 to 80% of trial averages.

Will Efinopegdutide Help with My Fatty Liver?

If you have MASH or significant hepatic steatosis, the phase 2 data is encouraging. Patients without significant liver fat would still see weight loss benefits without the liver-specific advantages.

Can I Expect 15% Weight Loss on Efinopegdutide?

Mean was 8.5% at 24 weeks. Individual results vary; some patients lose more.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.